Bayer AG said four of its drugs in development may become blockbusters, ultimately contributing 5 billion euros ($6.5 billion) to annual revenue.
Blood-thinner Xarelto has the brightest prospects, with peak sales probably exceeding 2 billion euros a year, Leverkusen, Germany-based Bayer said in a statement on its website today. Bayer’s eye drug VEGF Trap-Eye and cancer medicines Alpharadin and regorafenib have billion euro potential, the drugmaker said.
